IgG4-RD research and clinical trials
As a rare disease, research and clinical trials are critical to making progress. We aim to keep you up to date on the latest news and information.
IgG4-RD research and clinical trials
As a rare disease, research and clinical trials are critical to making progress. We aim to keep you up to date on the latest news and information.
What is a clinical trial?
A clinical trial is a research study that tests a new drug to determine the safety and efficacy of the treatment. Information and results from clinical trials are used by regulators, such as the Food and Drug Administration (FDA) in the U.S., to determine if a treatment should be approved for use by the general public.
Why clinical trials matter to you?
As a person living with IgG4-RD, staying up to date and even considering participation in a clinical trial is important. It is during these trials that the efficacy and safety of breakthrough drug treatments are made, and can unlock new options for how you manage this rare disease. Learn more by reading about the MITIGATE and INDIGO trials below, and reach out to us if you think trial participation might be of interest.
Featured trials
A study of inebilizumab efficacy and safety in IgG4-RD
Trial status: Recruitment complete
A Phase 3 Study of obexelimab in patients with IgG4-RD (INDIGO)
Trial status: Active, not recruiting
The MITIGATE trial
The IgG4ward! Foundation is delighted to announce the publication of the MITIGATE trial in the New England Journal of Medicine. MITIGATE, the first world-wide clinical trial ever performed in people living with IgG4-RD, confirmed the effectiveness of B cell depletion treatment in this condition. Treatment with inebilizumab in the trial reduced the risk of disease flare in the investigational treatment group by a remarkable 87%.
